ImStar Therapeutics

ImStar Therapeutics

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

Edit ID  8743701 

Dawson Sewell
Dawson Sewell edited on 1 Dec, 2018
Edits made to:
Infobox (+2 properties)
Description (+109/-54 characters)
Article (+817 characters)
People (+5 rows) (+10 cells) (+165/-7 characters)
Further reading (+2 rows) (+8 cells) (+429 characters)
Categories (+1 topics)
Topic thumbnail

ImStar Therapeutics

A company transforming ALS & Neurodegenerative Disease

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.

ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.

Funding

Seed Round

On June 8, 2016 ImStar Therapeutics closed their seed funding round with $1.8 million in funding from BDC Venture Capital and Accel-Rx Health Sciences Accelerator.

People

Name
Role
Related Golden topics

Agnes Chan

COO

Daniel Wattier

FounderCo-Founder & CEO

David Hunt

Senior Vice President, Research and Development

Jean Pierre Julien

Co-Founder & CSO

Jeff Charpentier

CFO

Julia Levy

Board Chair

Further reading

Title
Author
Link
Type

ImStar Therapeutics Selects Lead Drug Candidate for ALS

ImStar Therapeutics

News

Infobox
Categories
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.